Related Experiment Videos

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype

|October 1, 1996

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.

Oncogenesis·2014

Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.

Leukemia·2012

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Leukemia·2012

Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.

Cell death & disease·2011

Do we have to kill the last CML cell?

Leukemia·2010

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Leukemia·2010

See all related articles